- Hikma Pharmaceuticals on Thursday inked an exclusive agreement with Beijing Sciecure Pharmaceutical to sell one of latter's injectable anti-viral medicines across the US for a minimum of eight years, with an option to extend this partnership for an additional two years.

Sciecure expected to file this product for approval with the US Food and Drug Administration in early 2019, Hikma said.

'Our partnership with Sciecure is another example of how Hikma is continuing to expand its pipeline, targeting both niche products and high-volume opportunities, in order to offer a broad portfolio of high-quality medicines to US patients, physicians and hospitals,' said Daniel Motto, Hikma's Executive Vice President of Commercial and Business Development.

At 10:02am: [LON:HIK] Hikma Pharmaceuticals PLC share price was -17.25p at 1687.75p

Story provided by